# A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.

> **NCT03894150** · PHASE1 · COMPLETED · sponsor: **Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.** · enrollment: 45 (actual)

## Conditions studied

- Refractory or Recurrent CD30+ Hematologic Malignancies

## Interventions

- **DRUG:** F0002-ADC

## Key facts

- **NCT ID:** NCT03894150
- **Lead sponsor:** Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-11
- **Primary completion:** 2020-07-01
- **Final completion:** 2024-03-12
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03894150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03894150, "A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03894150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*